TaiGen Biopharmaceuticals Holdings Limited
TWO: 4157.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ming-Chu Hsu
- Employees
- 52
- Headquarters
- Taipei, Taiwan
- IPO year
- 2013
- Market cap
- NT$6.7B
- Website
- https://www.taigenbiotech.com.tw
Loading 4157…
Loading profile data…Frequently asked questions about 4157
What does TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) do?
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabet...
Where does 4157.TWO trade?
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) trades on the Taipei Exchange.
What sector is 4157.TWO in?
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of TaiGen Biopharmaceuticals Holdings Limited?
Ming-Chu Hsu is the chief executive officer of TaiGen Biopharmaceuticals Holdings Limited (4157.TWO).
Where is TaiGen Biopharmaceuticals Holdings Limited headquartered?
TaiGen Biopharmaceuticals Holdings Limited is headquartered in Taiwan.
Does 4157.TWO pay a dividend?
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4157.TWO go public?
TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) completed its initial public offering in 2013.